HIGHMARK COMMERCIAL MEDICAL POLICY - PENNSYLVANIA

 
 

Medical Policy:
S-121-022
Topic:
Liver Transplant
Section:
Surgery
Effective Date:
October 1, 2023
Issued Date:
October 1, 2023
Last Revision Date:
September 2023
Annual Review:
October 2022
 
 

Liver transplantation is currently the treatment of last resort for individuals with end-stage liver disease. Liver transplantation may be performed with a liver donation after a brain or cardiac death or with a liver segment donation from a living donor. Individuals are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network (OPTN) and the United Network of Organ Sharing (UNOS). The severity of illness is determined by the Model for End-stage Liver Disease (MELD) and Pediatric End-stage Liver Disease (PELD) scores.

Policy Position

A liver transplant using a cadaver or living donor may be considered medically necessary for carefully selected individuals with end-stage liver failure due to irreversibly damaged livers. Etiologies of end-stage liver disease include, but are not limited to ANY of the following;

  • Hepatocellular Diseases:
    • Alcoholic liver disease; or
    • Viral hepatitis (either A, B, C, or non-A, non-B); or
    • Autoimmune hepatitis; or
    • α1-Antitrypsin deficiency; or
    • Hemochromatosis; or
    • Nonalcoholic steatohepatitis; or
    • Protoporphyria; or
    • Wilson disease; or
  • Cholestatic liver diseases:
    • Primary biliary cirrhosis; or
    • Primary sclerosing cholangitis with development of secondary biliary cirrhosis; or
    • Biliary atresia; or
  • Vascular disease:
    • Budd-Chiari syndrome; or
  • Primary Hepatocellular Carcinoma; or
  • Inborn Errors of Metabolism; or
  • Trauma and toxic reactions; or
  • Miscellaneous:
    • Familial amyloid polyneuropathy.

Liver transplantation may be considered medically necessary in individuals with polycystic disease of the liver who have massive hepatomegaly causing obstruction or functional impairment.

 

Liver transplantation may be considered medically necessary in individuals with unresectable hilar cholangiocarcinoma.

 

Liver transplantation may be considered medically necessary in pediatric individuals with nonmetastatic hepatoblastoma as per UNOS and OPTN guidelines.

 

Liver retransplantation may be considered medically necessary in individuals with ANY of the following:

  • Primary graft nonfunction; or
  • Hepatic artery thrombosis; or
  • Chronic rejection; or
  • Ischemic type biliary lesions after donation after cardiac death; or
  • Recurrent non-neoplastic disease-causing late graft failure.

Liver transplantation is experimental and investigational and therefore non-covered because the safety/and/or effectiveness of this service cannot be established by the available published peer-reviewed literature for the following situations:

  • Individuals with intrahepatic cholangiocarcinoma; or
  • Individuals with neuroendocrine tumors metastatic to the liver.

Liver transplantation is considered not medically necessary in ANY of the following individuals;

  • Individuals with hepatocellular carcinoma that has extended beyond the liver; or
  • Individuals with ongoing alcohol and/or drug abuse:
    • Note: Evidence for abstinence may vary among liver transplant programs, but generally a minimum of three (3) months is required.

Liver transplantation not meeting the criteria as indicated in this policy is considered not medically necessary.

In addition to the above criteria and subject to the discretion of the transplant center, a Hepatitis C Virus (HCV) positive donor organ may be considered medically necessary as an acceptable organ option for an HCV negative adult recipient 18 years of age or older.

47133

47135

47140

47141

47142

47143

47144

47145

47146

47147

47399

 

 

 




Contraindications

Potential contraindications for solid organ transplant are subject to the judgment of the transplant center and may include but is not limited to the following:

  • Known current malignancy, including metastatic cancer; or
  • Recent malignancy with high risk of recurrence; or
  • Untreated systemic infection making immunosuppression unsafe, including chronic infection; or
  • Other irreversible end-stage diseases not attributed to liver disease; or
  • History of cancer with a moderate risk of recurrence; or
  • Systemic disease that could be exacerbated by immunosuppression; or
  • Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

Liver-Specific Criteria

The  MELD and PELD scores range from six (6) (less ill) to 40 (gravely ill). The MELD and PELD scores will change during an individual's tenure on the waiting list.

 

Individuals with liver disease related to alcohol or drug abuse must be actively involved in a substance abuse treatment program.

 

Tobacco consumption is a contraindication.

 

Individuals with polycystic disease of the liver do not develop liver failure but may require transplantation

due to the anatomic complications of a hugely enlarged liver. The MELD and PELD score may not apply to these cases. One of the following complications should be present:

  • Enlargement of liver impinging on respiratory function; or
  • Extremely painful enlargement of liver; or
  • Enlargement of liver significantly compressing and interfering with function of other abdominal organs.

Individuals with familial amyloid polyneuropathy do not experience liver disease per se, but develop polyneuropathy and cardiac amyloidosis due to the production of a variant transthyretin molecule by the liver. MELD and PELD exception criteria and scores may apply to these cases. Candidacy for liver transplant is an individual consideration based on the morbidity of the polyneuropathy. Many individuals may not be candidates for liver transplant alone due to coexisting cardiac disease; or

 

Hepatocellular Carcinoma

Criteria used for individual selection of hepatocellular carcinoma (HCC) individuals eligible for liver transplant include the Milan criteria, which is considered the criterion standard, the University of California, San Francisco expanded criteria, and United Network of Organ Sharing (UNOS) criteria.

 

Milan Criteria

A single tumor five (5) cm or less or two (2) to three (3) tumors three (3) cm or less.

 

University of California, San Francisco Expanded Criteria

A single tumor 6.5 cm or less or up to three (3) tumors 4.5 cm or less, and a total tumor size of eight (8) cm or less.

 

UNOS Stage T2 Criteria

A single tumor two (2) cm or greater and up to five (5) cm or less or two (2) to three (3) tumors one (1) cm or greater and up to three (3) cm or less and without extrahepatic spread or macrovascular invasion.

 

Individuals with HCC are appropriate candidates for liver transplant only if the disease remains confined to the liver. Therefore, the individual should be periodically monitored while on the waiting list, and if metastatic disease develops, the individual should be removed from the transplant waiting list. Also, at the time of transplant, a backup candidate should be scheduled. If locally extensive or metastatic cancer is discovered at the time of exploration before hepatectomy, the transplant should be aborted, and the backup candidate scheduled for transplant.

 

Note that liver transplant for those with T3 HCC is not prohibited by UNOS guidelines, but such individuals do not receive any priority on the waiting list. All individuals with HCC awaiting transplant are reassessed at three (3) month intervals. Those whose tumors have progressed and are no longer stage T2 will lose the additional allocation points.

 

Additionally, nodules identified through imaging of cirrhotic livers are given a class five (5) designation. Class 5B and 5T nodules are eligible for automatic priority. Class 5B criteria consist of a single nodule two (2) cm or larger and up to five (5) cm (T2 stage) that meets specified imaging criteria. Class 5T nodules have undergone subsequent locoregional treatment after being automatically approved on initial application or extension. A single class 5A nodule (greater than one (1) cm and less than two (2) cm) corresponds to T1 HCC and does not qualify for automatic priority. However, combinations of class 5A nodules are eligible for automatic priority if they meet stage T2 criteria. Class 5X lesions are outside of stage T2 and ineligible for automatic exception points. Nodules less than one (1) cm are considered indeterminate and are not considered for additional priority. Therefore, the UNOS allocation system. provides strong incentives to use locoregional therapies to downsize tumors to T2 status and to prevent progression while on the waiting list.

 

Cholangiocarcinoma

According to the Organ Procurement and Transplant Network policy on liver allocation, candidates with cholangiocarcinoma meeting the following criteria will be eligible for a MELD or PELD exception with a 10% mortality equivalent increase every three (3) months:

  • Centers must submit a written protocol for individual care to the OPTN and UNOS Liver and Intestinal Organ Transplant Committee before requesting a MELD score exception for a candidate with cholangiocarcinoma. This protocol should include selection criteria, administration of neoadjuvant therapy before transplant, and operative staging to exclude individuals with regional hepatic lymph node metastases, intrahepatic metastases, and/or extrahepatic disease. The protocol should include data collection as deemed necessary by the OPTN and UNOS Liver and Intestinal Organ Transplant Committee; or
  • Candidates must satisfy diagnostic criteria for hilar cholangiocarcinoma: malignant-appearing stricture on cholangiography and one of the following: carbohydrate antigen 19-9 100 U/mL, or and biopsy or cytology results demonstrating malignancy, or aneuploidy. The tumor should be considered unresectable on the basis of technical considerations or underlying liver disease (eg, primary sclerosing cholangitis); or
  • If cross-sectional imaging studies (computed tomography scan, ultrasound, magnetic resonance imaging) demonstrate a mass, the mass should be three (3) cm or less; or
  • Intra- and extrahepatic metastases should be excluded by cross-sectional imaging studies of the chest and abdomen at the time of initial exception and every three (3) months before score increases; or
  • Regional hepatic lymph node involvement and peritoneal metastases should be assessed by operative staging after completion of neoadjuvant therapy and before liver transplant. Endoscopic ultrasound-guided aspiration of regional hepatic lymph nodes may be advisable to exclude individuals with obvious metastases before neoadjuvant therapy is initiated; or
  • Transperitoneal aspiration or biopsy of the primary tumor (either by endoscopic ultrasound, operative, or percutaneous approaches) should be avoided because of the high risk of tumor seeding associated with these procedures.

Living Donor Criteria

Donor morbidity and mortality are prime concerns in donors undergoing right lobe, left lobe, or left lateral segment donor partial hepatectomy as part of living donor liver transplant. Partial hepatectomy is a technically demanding surgery, the success of which may be related to the availability of an experienced surgical team. The American Society of Transplant Surgeons proposed the following guidelines for living donors (American Society of Transplant Surgeons: Ethics Committee. American Society of Transplant Surgeons' position paper on adult-to-adult living donor liver transplant;

  • They should be healthy individuals who are carefully evaluated and approved by a multidisciplinary team including hepatologists and surgeons to assure that they can tolerate the procedure; or
  • They should undergo evaluation to ensure that they fully understand the procedure and associated risks; or
  • They should be of legal age and have sufficient intellectual ability to understand the procedures and give informed consent; or
  • They should be emotionally related to the recipients; or
  • They must be excluded if the donor is felt or known to be coerced; or
  • They need to have the ability and willingness to comply with long-term follow-up. 

Related Policies

Refer to Medical Policy S-118, Small Bowel, Small Bowel/Liver and Multivisceral Transplantation, for additional information.


Professional Statements and Societal Positions Guidelines

American Association for the Study of Liver Diseases et al-2013

The American Association for the Study of Liver Diseases and the American Society of Transplantation (2013) issued joint guidelines on evaluating patients for liver transplant. These guidelines indicated liver transplantation for severe acute or advanced chronic liver disease after all effective medical treatments have been attempted. The formal evaluation should confirm the irreversible nature of the liver disease and lack of effective alternative medical therapy.

The guidelines also stated that liver transplant is indicated for the following conditions:

  • Acute liver failure complications of cirrhosis
  • Liver-based metabolic condition with systemic manifestations
  • Systemic complications of chronic liver disease. 

The guidelines also included 1-A recommendations (strong recommendation with high-quality evidence) for a liver transplant that:

  • “Tobacco consumption should be prohibited in LT [liver transplant] candidates.” 
  • “Patients with HIV infection are candidates for LT if immune function is adequate and the virus is expected to be undetectable by the time of LT.” 
  • “LT candidates with HCV [hepatitis C virus] have the same indications for LT as for other etiologies of cirrhosis.” 
  • Contraindications to liver transplant included: 
    • “MELD [Model for End-stage Liver Disease] score less than15 
    • Severe cardiac or pulmonary disease 
    • AIDS 
    • Ongoing alcohol or illicit substance abuse 
    • Hepatocellular carcinoma with metastatic spread 
    • Uncontrolled sepsis 
    • Anatomic abnormality that precludes liver transplantation
    • Intrahepatic cholangiocarcinoma 
    • Extrahepatic malignancy 
    • Fulminant hepatic failure 
    • Hemangiosarcoma 
    • Persistent noncompliance 
    • Lack of adequate social support system.” 

The American Association for the Study of Liver Diseases, the American Society of Transplantation, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition issued joint guidelines on the evaluation of the pediatric patients for liver transplant in 2014. The guidelines stated that “disease categories suitable for referral to a pediatric LT program are similar to adults: acute liver failure, autoimmune, cholestasis, metabolic or genetic, oncologic, vascular, and infectious. However, specific etiologies and outcomes differ widely from adult patients, justifying independent pediatric guidelines.” The indications listed for liver transplantation included biliary atresia, Alagille syndrome, pediatric acute liver failure, hepatic tumors, HCC, hemangioendothelioma, cystic fibrosis-associated liver disease, urea cycle disorders, immune-mediated liver disease, along with other metabolic or genetic disorders.

National Comprehensive Cancer Network-2022

Hepatocellular Carcinoma

The National Comprehensive Cancer Network (NCCN) guidelines on hepatobiliary cancers (v.2.2022) recommend referral to a liver transplant center or bridge therapy for patients with HCC meeting United Network of Organ Sharing criteria of a single tumor measuring 2 to 5 cm, or 2 to 3 tumors 1-3 cm in diameter with no macrovascular involvement or no extrahepatic disease. Patients should be referred to the transplant center before the biopsy. In patients who are ineligible for transplant and in select patients with Child-Pugh class A or B liver function with tumors that are resectable, NCCN indicates resection is the preferred treatment option; locoregional therapy may also be considered. Patients with unresectable HCC should be evaluated for liver transplantation; if the patient is a transplant candidate, then referral to a transplant center should be given or bridge therapy should be considered.

Neuroendocrine and Adrenal Tumors

The NCCN guidelines on neuroendocrine tumors (v.1.2022) indicate that liver transplantation included for neuroendocrine metastases confined to the liver is considered investigational despite “encouraging” 5-year survival rates.


Covered diagnosis for procedure codes 47133, 47135, 47140, 47141, 47142, 47143, 47144, 47145, 47146, 47147, 47399

B15.0

B15.9

B16.0

B16.1

B16.2

B16.9

B17.10

B17.11

B17.8

B17.9

B18.0

B18.1

B18.2

B18.8

B18.9

B19.0

B19.10

B19.11

B19.20

B19.21

B19.9

B25.1

B66.1

B66.3

C22.0

C22.1

C22.2

C22.3

C22.4

C22.7

C22.8

C22.9

E70.0

E70.1

E70.20

E70.21

E70.29

E70.30

E70.310

E70.311

E70.318

E70.319

E70.320

E70.321

E70.328

E70.329

E70.330

E70.331

E70.338

E70.339

E70.39

E70.40

E70.41

E70.49

E70.5

E70.9

E71.0

E71.110

E71.111

E71.118

E71.120

E71.121

E71.128

E71.19

E71.2

E71.30

E71.310

E71.311

E71.312

E71.313

E71.314

E71.318

E71.32

E71.39

E71.40

E71.41

E71.42

E71.43

E71.440

E71.448

E71.50

E71.510

E71.511

E71.518

E71.520

E71.521

E71.522

E71.528

E71.529

E71.53

E71.540

E71.541

E71.542

E71.548

E72.00

E72.01

E72.02

E72.03

E72.04

E72.09

E72.10

E72.11

E72.12

E72.19

E72.20

E72.21

E72.22

E72.23

E72.29

E72.3

E72.4

E72.50

E72.51

E72.52

E72.53

E72.59

E72.81

E72.89

E72.9

E74.00

E74.01

E74.02

E74.03

E74.04

E74.09

E74.10

E74.11

E74.12

E74.19

E74.20

E74.21

E74.29

E74.31

E74.39

E74.4

E74.9

E78.0

E78.01

E78.1

E78.2

E78.3

E78.41

E78.49

E78.5

E78.6

E78.70

E78.79

E78.81

E78.89

E78.9

E80.0

E80.1

E80.20

E80.21

E80.29

E83.00

E83.01

E83.09

E83.10

E83.110

E83.111

E83.118

E83.119

E83.19

E85.0

E85.1

E85.2

E85.3

E85.4

E85.81

E85.82

E85.89

E85.9

E88.09

E88.1

E88.2

E88.3

E88.40

E88.41

E88.42

E88.49

E88.89

E88.9

E88.01

G63

I74.8

I82.0

K70.2

K70.30

K70.31

K70.40

K70.41

K70.9

K71.0

K71.10

K71.11

K71.2

K71.3

K71.4

K71.50

K71.51

K71.6

K71.7

K71.8

K71.9

K72.00

K72.01

K72.10

K72.11

K72.90

K72.91

K73.2

K73.9

K74.00

K74.01

K74.02

K74.3

K74.4

K74.5

K74.60

K74.69

K75.2

K75.3

K75.4

K75.81

K76.0

K76.2

K76.3

K76.4

K76.5

K76.7

K76.89

K77

K83.0

K83.1

K83.5

K83.8

Q44.1

Q44.2

Q44.3

Q44.4

Q44.5

Q44.6

Q44.70

Q44.71

Q44.79

S36.112A

S36.112D

S36.112S

S36.113A

S36.113D

S36.113S

S36.114A

S36.114D

S36.114S

S36.115A

S36.115D

S36.115S

S36.116A

S36.116D

S36.116S

S36.118A

S36.118D

S36.118S

S36.119A

S36.119D

S36.119S

T86.40

T86.41

T86.42

T86.43

T86.49

Z52.6

 



Place of Service: Inpatient

Experimental/Investigational (E/I) services are not covered regardless of place of service.



The policy position applies to all commercial lines of business



Links






This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical or other circumstances may warrant individual consideration, based on review of applicable medical records, as well as other regulatory, contractual and/or legal requirements.

Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect Highmark's reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract, and subject to the applicable laws of your state.


Highmark retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.

Discrimination is Against the Law
The Claims Administrator/Insurer complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The Claims Administrator/Insurer does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. The Claims Administrator/ Insurer:

  • Provides free aids and services to people with disabilities to communicate effectively with us, such as: 
    • Qualified sign language interpreters
    • Written information in other formats (large print, audio, accessible electronic formats, other formats)
  • Provides free language services to people whose primary language is not English, such as: 
    • Qualified interpreters
    • Information written in other languages

If you need these services, contact the Civil Rights Coordinator. 

If you believe that the Claims Administrator/Insurer has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, P.O. Box 22492, Pittsburgh, PA 15222, Phone: 1-866-286-8295, TTY: 711, Fax: 412-544-2475, email: CivilRightsCoordinator@highmarkhealth.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. 

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: 

U.S. Department of Health and Human Services 
200 Independence Avenue, SW 
Room 509F, HHH Building 
Washington, D.C. 20201 
1-800-368-1019, 800-537-7697 (TDD) 

Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. 

Insurance or benefit/claims administration may be provided by Highmark, Highmark Choice Company, Highmark Coverage Advantage, Highmark Health Insurance Company, First Priority Life Insurance Company, First Priority Health, Highmark Benefits Group, Highmark Select Resources, Highmark Senior Solutions Company or Highmark Senior Health Company, all of which are independent licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. 





Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.

Discrimination is Against the Law
The Claims Administrator/Insurer complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The Claims Administrator/Insurer does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. The Claims Administrator/ Insurer:

  • Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)

  • Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages
  • If you need these services, contact the Civil Rights Coordinator.

    If you believe that the Claims Administrator/Insurer has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, P.O. Box 22492, Pittsburgh, PA 15222, Phone: 1-866-286-8295 , TTY: 711, Fax: 412-544-2475, email: CivilRightsCoordinator@highmarkhealth.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

    You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

    U.S. Department of Health and Human Services
    200 Independence Avenue, SW
    Room 509F, HHH Building
    Washington, D.C. 20201
    1-800-368-1019, 800-537-7697 (TDD)

    Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.